STADA, the owner of various consumer healthcare products and the Zoflora cleaning brand, is expanding its European portfolio by acquiring another range of local and regional brands from Sanofi in countries including Belgium, Germany, Hungary, Spain and the UK, as well as Nordic countries.
The transaction covers several brands, including Antistax for pain relief and tiredness in legs; the allergy eye drops Lomudal; Omnivit vitamins; and Opticrom allergy eye drops. In addition, the two painkillers AAS and Dolalgial, as well as Bila-Git for gallbladder complaints, are part of the acquired portfolio.
The transaction for an undisclosed sum is scheduled to close in the fourth quarter of this year, subject to customary approvals of relevant regulatory authorities.
STADA’s CEO, Peter Goldschmidt, commented: “We are pleased to continue our collaboration with Sanofi. This acquisition further strengthens STADA as a top-four player in Europe’s consumer healthcare market and supports our growth acceleration along our purpose of ‘Caring for People’s Health as a Trusted Partner’.
He added: “The brands being acquired, and their geographic presence, are well aligned and synergistic with the organic activities in STADA’s core countries.”
Meanwhile, STADA’s Western Europe and Germany Head, Stephan Eder, said: “This acquisition is the next step towards being the leader in local market brands. STADA’s extensive sales, marketing and distribution network throughout Europe, along with our long-established partnerships with pharmacists, will enable the group to grow these brands by also developing additional offerings.
“By further developing these well-known brands, we are strengthening our compelling and comprehensive offering to customers across our three strategic pillars: Consumer Healthcare, Specialty and Generics in key, predominantly Western European countries.”
